Toronto Dominion Bank Purchases Shares of 1,749,142 UroGen Pharma Ltd. (NASDAQ:URGN)

Toronto Dominion Bank bought a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,749,142 shares of the company's stock, valued at approximately $18,628,000. Toronto Dominion Bank owned 7.46% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in URGN. Renaissance Technologies LLC bought a new position in UroGen Pharma in the fourth quarter valued at about $1,472,000. Lazard Asset Management LLC bought a new position in shares of UroGen Pharma in the 4th quarter valued at about $67,000. Bank of New York Mellon Corp grew its position in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after buying an additional 6,430 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of UroGen Pharma during the fourth quarter worth approximately $126,000. Finally, Janus Henderson Group PLC bought a new stake in shares of UroGen Pharma during the fourth quarter worth approximately $149,000. 91.29% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Guggenheim reduced their price objective on shares of UroGen Pharma from $40.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 23rd. Scotiabank initiated coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Thursday, May 8th. HC Wainwright downgraded shares of UroGen Pharma from a "buy" rating to a "neutral" rating in a research report on Thursday, May 22nd. Finally, The Goldman Sachs Group decreased their price objective on shares of UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma presently has an average rating of "Moderate Buy" and an average price target of $27.43.

UroGen Pharma Stock Down 2.0%

Shares of NASDAQ URGN traded down $0.08 during mid-day trading on Thursday, reaching $3.97. 2,334,280 shares of the company's stock were exchanged, compared to its average volume of 693,741. UroGen Pharma Ltd. has a twelve month low of $3.42 and a twelve month high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $183.04 million, a price-to-earnings ratio of -1.26 and a beta of 0.66. The business has a fifty day simple moving average of $9.56 and a 200 day simple moving average of $10.50.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. As a group, equities analysts expect that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.